G6PD and breast cancer: Therefore, the codelivery of G6PD inhibitors (such as RRx-001) and sonosensitizers in tumor tissues to deplete GSH and disrupt redox homeostasis may maximally enhance the treatment efficiency of SDT in breast cancer.